OptumRx has recently announced that it is easing its prior authorization (PA) requirements on about 80 drugs for renewed prescriptions. The program is planned to start on May 1, 2025 and will include various drugs such as Aimovig, Kalydeco, and
Pharmacy & Healthcare Legal Blog
Pharmacy & Healthcare legal updates, news, and industry trends
The Pharmacy & Healthcare Legal Blog, published by Mazina Law, focuses on legal issues affecting pharmacies and healthcare providers. Topics include regulatory compliance with Medicare Part D reimbursement changes, DEA prescription audits, and state-specific pharmacy closure notification requirements. The blog also covers manufacturer audits and data requests, medication error reporting mandates, and practical guidance for independent pharmacies navigating evolving legal and operational challenges. It addresses both federal and state pharmacy law, reimbursement policies, and risk management strategies relevant to pharmacy owners and healthcare legal professionals.
Latest from Pharmacy & Healthcare Legal Blog - Page 2
(Very) Short overview of the ASPL conference: Focus on Controlled Substances
Governor Newsom denied a bill aimed at increasing transparency of the PBM market
Our April 29th post discussed the introduction of SB 966 that would have required PBMs doing business in California to be licensed and regulated. The Bill had passed all relevant committees and landed on the Governor’s desk in September of…
A wave of extensive Medi-Cal audits overwhelms California pharmacies
Next Webinar: Compliance with the Controlled Substances Act and Highlights from DEA audits of Hospital Pharmacies
FDA postpones compliance with DSCSA for small dispensers. What does it mean for pharmacies?
The second-largest criminal fine – $1.53 billion – levied against a pharmaceutical company
Updates on California’s proposed PBM bill
Earlier this year, California Senator Scott Wiener (D-San Francisco) introduced SB 966 that would require PBMs doing business in California to be licensed and regulated. The objective is to curb PBMs anticompetitive practices contributing to rising drug costs. The press…